Loading viewer...
investor_presentation
Format: PDF investor_presentation
ESSA Pharma is a biopharmaceutical company focused on developing novel therapies for prostate and androgen-driven cancers. Its lead candidate EPI-7386, a first-in-class oral androgen receptor N-terminal domain inhibitor, is in late-stage development for metastatic castration-resistant prostate cancer as both a monotherapy and in combination with leading antiandrogens. The company is headquartered in South San Francisco and Vancouver with cash runway through 2025.
presentation
investor_presentation
9 Pages
Automotive Axles Limited
Hathway Cable Datacom Investor Presentation August 2017
investor_presentationinvestor_presentation
34 Pages
Hathway Cable and Datacom Limited